VWF: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of VWF. The page also collects GeneMedi's different modalities and formats products for VWF in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the VWF target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Secreted Protein/Potential Cytokines.
This gene encodes a glycoprotein involved in hemostasis. The encoded preproprotein is proteolytically processed following assembly into large multimeric complexes. These complexes function in the adhesion of platelets to sites of vascular injury and the transport of various proteins in the blood. Mutations in this gene result in von Willebrand disease, an inherited bleeding disorder. An unprocessed pseudogene has been found on chromosome 22. [provided by RefSeq, Oct 2015]
Target ID | GM-T23348 |
Target Name | VWF |
Gene ID | 7450,22371,116669,722019,399544,493760,280958,100059472 |
Gene Symbol and Synonyms | 6820430P06Rik,B130011O06Rik,C630030D09,F8VWF,VWD,VWF |
Uniprot Accession | P04275,Q62935,Q28295,P80012 |
Uniprot Entry Name | VWF_HUMAN,VWF_RAT,VWF_CANLF,VWF_BOVIN |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | Therapeutics Target, INN Index |
Disease | Ovary Cancer |
Gene Ensembl | ENSG00000110799 |
Target Classification | N/A |
Pre-made VWF-specific INN-index biosimilar (antibody&conjugates)
Anti-VWF therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Cat No. | Products Name (INN Index) | INN Name | Previous Name | Target | Format | Detail |
GMP-Bios-ab-093 | Pre-Made Caplacizumab biosimilar, Nanobody, Anti-VWF Antibody: Anti-F8VWF/VWD therapeutic antibody | Caplacizumab | VWF | Nanobody | Detail |
Click to check more INN-indexed antibody & protein biosimilar
Pre-made anti-VWF inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-VWF benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-VWF mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Antibody Name | Species | Format | Classified by tag | Detail |
Anti-VWF monoclonal antibody | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | mab | FACS/Biofunctional Antibody, Therapeutics Target antibody | Detail |
Recombinant multi-species VWF/ F8VWF/ VWD protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine VWF protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Products Name | Species | Expression Platform | Detail |
VWF protein | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | Mammalian cell | Detail |